Enrico Martin

166 Chapter 7 Table 1 Continued. Author, year Model Regimen Pathway Tissue NF1 a Outcome Growth b Survival c Metastasis d Malone, 2017 GEMM Sapanisertib + panobinostat mTOR, HDAC NPcis NA NA NA Semenova, 2017 XM Frax1036 +/- PD0325901 PAK1, MEK S462TY NF1 NA NA STS26T S NA Nuclear targets Hirokawa, 2005 XM Depsipeptide HDAC S805 NF1 NA NA Lopez, 2011 XM Abexinostat + chloroquine HDAC, autophagy MPNST642 NF1 NA NA MPNST724 S NA NA STS26T S NA Patel, 2012 XM Alisertib AURKA S462TY NF1 NA Mohan, 2013 XM Alisertib AURKA NF1-MPNST NF1 NA NA SP-MPNST S NA NA Patel, 2014 AA JQ1 BET sMPNST NA NA NA Lopez, 2015 AA PCI-48012 HDAC8 MPNST6IEPVI NA NA NA Nair, 2015 XM TAK-960 PLK1 MPNST NA NA NA Perez, 2015 XM Palbociclib CDK4/6 S14 NA NA Zhang, 2015 XM DZNep EZH2 MPNST724 S NA NA Kivlin, 2016 XM Olaparib PARP STS26T S NA MPNST724 S NA NA Nair, 2017 XM Selinexor + carfilzomib XPO1, proteasome MPNST NA NA NA Payne, 2018 OXM Alisertib AURKA STS26T S NA NA Immunotherapy and oncolytic viruses Liu, 2006 AA G47∆-PF4 oHSV M2 NA NA Liu, 2006 AA G47∆-dnFGFR oHSV M2 NA NA NA Mahller, 2007 XM hrR3 oHSV STS26T S NA Mahller, 2008 XM rQT3 oHSV STS26T S NA NA S462TY NF1 NA Maldonado, 2010 XM oHSV-MDK-34.5 oHSV STS26T S NA